LOND\u00ddN – Nov\u00e1 g\u00e9nov\u00e1 terapia priniesla v\u00fdsledky, ktor\u00e9 vzbudili ve\u013ek\u00e9 o\u010dak\u00e1vania. Pod\u013ea vedcov by v bud\u00facnosti mohla nahradi\u0165 dlhodob\u00e9 u\u017e\u00edvanie liekov na cholesterol a pacientom by sta\u010dila jedin\u00e1 inf\u00fazia.<\/p>\n
Kardiovaskul\u00e1rne ochorenia patria dlhodobo medzi naj\u010dastej\u0161ie pr\u00ed\u010diny \u00famrt\u00ed na svete. V\u00fdznamn\u00fdm rizikov\u00fdm faktorom je pritom zv\u00fd\u0161en\u00e1 hladina LDL cholesterolu, zn\u00e1meho aj ako \u201ezl\u00fd cholesterol\u201c.<\/p>\n
Pr\u00e1ve preto vzbudila ve\u013ek\u00fa pozornos\u0165 nov\u00e1 \u0161t\u00fadia, ktorej v\u00fdsledky nazna\u010duj\u00fa, \u017ee boj s vysok\u00fdm cholesterolom by sa v bud\u00facnosti mohol z\u00e1sadne zmeni\u0165.<\/p>\n
V\u00fdskumn\u00edci testovali experiment\u00e1lnu g\u00e9nov\u00fa terapiu, ktor\u00e1 po jedinom podan\u00ed v\u00fdrazne zn\u00ed\u017eila hladinu LDL cholesterolu. O v\u00fdsledkoch informoval magaz\u00edn Time<\/a> s odvolan\u00edm sa na \u0161t\u00fadiu publikovan\u00fa 25. m\u00e1ja v prest\u00ed\u017enom odbornom \u010dasopise New England Journal of Medicine<\/a>.<\/p>\n V\u00fdsledky prekonali o\u010dak\u00e1vania<\/p>\n Do sk\u00fa\u0161ania sa zapojilo 35 dobrovo\u013en\u00edkov. U nich sa po podan\u00ed lie\u010dby podarilo zn\u00ed\u017ei\u0165 hladinu LDL cholesterolu o 9 a\u017e 62 percent v z\u00e1vislosti od pou\u017eitej d\u00e1vky.<\/p>\n V\u00fdskum realizovala spolo\u010dnos\u0165 Verve Therapeutics, ktor\u00e1 patr\u00ed pod farmaceutick\u00fd koncern Eli Lilly.<\/p>\n Vedci sa zamerali na g\u00e9n ozna\u010dovan\u00fd ako PCSK9, ktor\u00fd zohr\u00e1va d\u00f4le\u017eit\u00fa \u00falohu pri regul\u00e1cii cholesterolu v organizme.<\/p>\n U\u017e pribli\u017ene pred dvoma desa\u0165ro\u010diami odborn\u00edci z UT Southwestern Medical Center zistili, \u017ee \u013eudia s prirodzenou mut\u00e1ciou tohto g\u00e9nu maj\u00fa mimoriadne n\u00edzke hodnoty LDL cholesterolu a z\u00e1rove\u0148 ni\u017e\u0161ie riziko infarktu \u010di in\u00fdch srdcovo-cievnych komplik\u00e1ci\u00ed.<\/p>\n G\u00e9n, ktor\u00fd ovplyv\u0148uje cholesterol<\/p>\n PCSK9 p\u00f4sob\u00ed najm\u00e4 v pe\u010deni, kde sa podie\u013ea na procesoch reguluj\u00facich hladinu cholesterolu v krvi.<\/p>\n Vedci zistili, \u017ee u \u013eud\u00ed s neakt\u00edvnou verziou g\u00e9nu zost\u00e1vaj\u00fa hodnoty LDL prirodzene n\u00edzke bez v\u00fdznamn\u00fdch negat\u00edvnych zdravotn\u00fdch n\u00e1sledkov.<\/p>\n Pr\u00e1ve tento objav viedol k v\u00fdvoju modern\u00fdch liekov, ktor\u00e9 aktivitu g\u00e9nu blokuj\u00fa. V s\u00fa\u010dasnosti s\u00fa schv\u00e1len\u00e9 \u0161tyri tak\u00e9to pr\u00edpravky ur\u010den\u00e9 na zni\u017eovanie cholesterolu.<\/p>\n Maj\u00fa v\u0161ak jednu nev\u00fdhodu.<\/p>\n Probl\u00e9mom je dlhodob\u00e1 lie\u010dba<\/p>\n Dostupn\u00e9 lieky sa pod\u00e1vaj\u00fa injek\u010dne a vy\u017eaduj\u00fa pravideln\u00e9 n\u00e1v\u0161tevy zdravotn\u00edckeho zariadenia alebo opakovan\u00e9 aplik\u00e1cie.<\/p>\n Pr\u00e1ve to je pod\u013ea odborn\u00edkov d\u00f4vod, pre\u010do ve\u013ek\u00e1 \u010das\u0165 pacientov lie\u010dbu po ur\u010ditom \u010dase preru\u0161\u00ed.<\/p>\n \u0160tatistiky ukazuj\u00fa, \u017ee pribli\u017ene 30 a\u017e 50 percent \u013eud\u00ed prestane lieky u\u017e\u00edva\u0165 pribli\u017ene do jedn\u00e9ho roka od za\u010diatku terapie. Podobn\u00fd probl\u00e9m existuje aj pri ka\u017edodennom u\u017e\u00edvan\u00ed stat\u00ednov.<\/p>\n Jedna inf\u00fazia namiesto rokov lie\u010dby<\/p>\n Experiment\u00e1lna terapia VERVE-102 sa sna\u017e\u00ed tento probl\u00e9m odstr\u00e1ni\u0165.<\/p>\n Jej cie\u013eom nie je do\u010dasne blokova\u0165 g\u00e9n PCSK9, ale priamo upravi\u0165 genetick\u00fa inform\u00e1ciu v pe\u010de\u0148ov\u00fdch bunk\u00e1ch tak, aby organizmus dlhodobo vytv\u00e1ral jeho neakt\u00edvnu verziu.<\/p>\n V\u00fdsledkom m\u00e1 by\u0165 trval\u00e9 zn\u00ed\u017eenie hladiny LDL cholesterolu bez potreby pravideln\u00fdch injekci\u00ed \u010di ka\u017edodenn\u00e9ho u\u017e\u00edvania liekov.<\/p>\n Vedci zd\u00f4raz\u0148uj\u00fa, \u017ee terapia s\u00edce nevytv\u00e1ra \u00faplne identick\u00fa genetick\u00fa zmenu, ak\u00fa maj\u00fa \u013eudia naroden\u00ed s prirodzene neakt\u00edvnym g\u00e9nom PCSK9, kone\u010dn\u00fd efekt by v\u0161ak mal by\u0165 ve\u013emi podobn\u00fd.<\/p>\n G\u00e9n sa prakticky vypne a hladina \u0161kodliv\u00e9ho cholesterolu v\u00fdrazne klesne.<\/p>\n V\u00fdskum je e\u0161te len na za\u010diatku<\/p>\n Napriek s\u013eubn\u00fdm v\u00fdsledkom odborn\u00edci upozor\u0148uj\u00fa, \u017ee terapia sa st\u00e1le nach\u00e1dza vo f\u00e1ze klinick\u00e9ho testovania a pred jej pr\u00edpadn\u00fdm schv\u00e1len\u00edm bude potrebn\u00e9 potvrdi\u0165 dlhodob\u00fa bezpe\u010dnos\u0165 aj \u00fa\u010dinnos\u0165 na v\u00e4\u010d\u0161om po\u010dte pacientov.<\/p>\n Ak sa v\u0161ak doteraj\u0161ie v\u00fdsledky potvrdia, mohlo by \u00eds\u0165 o jeden z najv\u00fdznamnej\u0161\u00edch pokrokov v lie\u010dbe vysok\u00e9ho cholesterolu za posledn\u00e9 desa\u0165ro\u010dia.<\/p>\n","protected":false},"excerpt":{"rendered":"LOND\u00ddN – Nov\u00e1 g\u00e9nov\u00e1 terapia priniesla v\u00fdsledky, ktor\u00e9 vzbudili ve\u013ek\u00e9 o\u010dak\u00e1vania. Pod\u013ea vedcov by v bud\u00facnosti mohla nahradi\u0165…\n","protected":false},"author":2,"featured_media":86435,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[8],"tags":[1245,31177,31178,33,5887,43,40,42,36,50,5343,49,48],"class_list":["post-86434","post","type-post","status-publish","format-standard","has-post-thumbnail","category-svet","tag-cholesterol","tag-infuzia","tag-ldl","tag-news","tag-objav","tag-sk","tag-slovak","tag-slovencina","tag-spravy","tag-svet","tag-vedci","tag-world","tag-world-news"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@sk\/116678645763602925","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/sk\/wp-json\/wp\/v2\/posts\/86434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/sk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/sk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/sk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/sk\/wp-json\/wp\/v2\/comments?post=86434"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/sk\/wp-json\/wp\/v2\/posts\/86434\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/sk\/wp-json\/wp\/v2\/media\/86435"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/sk\/wp-json\/wp\/v2\/media?parent=86434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/sk\/wp-json\/wp\/v2\/categories?post=86434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/sk\/wp-json\/wp\/v2\/tags?post=86434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}